Athan Kuliopulos, MD, PhD

Trials

Studies that name Athan Kuliopulos, MD, PhD as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 11:53 UTC. Open this list on ClinicalTrials.gov

• Ph1
  NCT05680233 · Safety Study of OA-235i in Subjects With Nonalcoholic Steatohepatitis

  Oasis Pharmaceuticals, LLC · completed · Nonalcoholic Steatohepatitis, Nonalcoholic Fatty Liver · study director
• Ph2
  NCT02561000 · Safety of PZ-128 in Subjects Undergoing Non-Emergent Percutaneous Coronary Intervention

  Tufts Medical Center · completed · Arterial Occlusive Diseases, Coronary Artery Disease, Coronary Disease · study director
• Ph1
  NCT01806077 · Safety Study of PZ-128 in Subjects With Multiple Coronary Artery Disease Risk Factors

  Tufts Medical Center · completed · Vascular Disease, Coronary Artery Disease Risk Factors Multiple · study director

Grants

NIH projects from RePORTER, fetched 2026-11-12 11:53 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 1 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.

No NIH project could be tied to this name by a shared trial or a matching institution.

NIH grants that fund their trials

These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.

• Development of PAR2 Pepducins as a Novel NASH Treatment
  R44DK101240 · NIDDK · OASIS PHARMACEUTICALS · PI Athan Kuliopulos · fiscal years 2017 to 2019
  Named on NCT05680233
• TRIP-PCI: PAR1 Pepducin-Based Interventions in Arterial Thrombosis
  P50HL110789 · NHLBI · TUFTS MEDICAL CENTER · PI ATHAN KULIOPULOS · fiscal years 2012 to 2016
  Named on NCT02561000, NCT01806077